Steroids for the Treatment of Misophonia and Misokinesia.

Q4 Medicine Case Reports in Psychiatry Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI:10.1155/2024/3976837
Jadon Webb, Afton Williamson
{"title":"Steroids for the Treatment of Misophonia and Misokinesia.","authors":"Jadon Webb, Afton Williamson","doi":"10.1155/2024/3976837","DOIUrl":null,"url":null,"abstract":"<p><p>Misophonia and misokinesia are disorders characterized by intensely negative physical and emotional reactions to specific auditory and visual stimuli. The availability of effective treatments, especially pharmacological ones, is limited. This report presents a case of a 35-year-old male with severe misophonia and misokinesia who experienced nearly complete resolution of symptoms while undergoing high-dose steroid therapy for an unrelated muscular injury. Two days after starting a 20 mg oral prednisone taper pack (in which the steroid dose is reduced by 4 mg daily), his Amsterdam Misophonia Scale (A-Miso-S) score drastically reduced from a baseline of 23 (i.e., extreme symptoms) to 1, with symptom relief persisting for approximately 2 weeks after completing the taper. Months later, a daily dose of prednisone (4 mg) was reintroduced. This again resulted in a marked reduction in symptoms (A-Miso-S of 6), enabling him to resume working in an office setting despite his triggers. Symptom improvement remained stable over several months. This case raises the possibility of the steroid prednisone as a novel treatment for misophonia and misokinesia. However, further investigation is needed to determine the generalizability of this observation.</p>","PeriodicalId":9631,"journal":{"name":"Case Reports in Psychiatry","volume":"2024 ","pages":"3976837"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10805550/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/3976837","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Misophonia and misokinesia are disorders characterized by intensely negative physical and emotional reactions to specific auditory and visual stimuli. The availability of effective treatments, especially pharmacological ones, is limited. This report presents a case of a 35-year-old male with severe misophonia and misokinesia who experienced nearly complete resolution of symptoms while undergoing high-dose steroid therapy for an unrelated muscular injury. Two days after starting a 20 mg oral prednisone taper pack (in which the steroid dose is reduced by 4 mg daily), his Amsterdam Misophonia Scale (A-Miso-S) score drastically reduced from a baseline of 23 (i.e., extreme symptoms) to 1, with symptom relief persisting for approximately 2 weeks after completing the taper. Months later, a daily dose of prednisone (4 mg) was reintroduced. This again resulted in a marked reduction in symptoms (A-Miso-S of 6), enabling him to resume working in an office setting despite his triggers. Symptom improvement remained stable over several months. This case raises the possibility of the steroid prednisone as a novel treatment for misophonia and misokinesia. However, further investigation is needed to determine the generalizability of this observation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用类固醇治疗失音症和运动失调症。
错视症和错动症是一种以对特定听觉和视觉刺激产生强烈的负面身体和情绪反应为特征的疾病。目前有效的治疗方法有限,尤其是药物治疗。本报告介绍了一例患有严重失音和运动失调的 35 岁男性患者,他在接受大剂量类固醇治疗期间,因与肌肉损伤无关而出现的症状几乎完全消失。在开始口服 20 毫克泼尼松减量包(类固醇剂量每天减少 4 毫克)两天后,他的阿姆斯特丹失音量表(A-Misophonia Scale,A-Miso-S)评分从基线 23 分(即极度症状)急剧下降至 1 分,症状缓解在完成减量后持续了约两周。几个月后,又开始每天服用泼尼松(4 毫克)。这再次导致症状明显减轻(A-Miso-S 为 6),使他能够在有诱发因素的情况下继续在办公室工作。症状的改善在几个月内保持稳定。本病例提出了类固醇泼尼松作为治疗失音和误动作的新疗法的可能性。然而,要确定这一观察结果是否具有普遍性,还需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Case Reports in Psychiatry
Case Reports in Psychiatry Medicine-Psychiatry and Mental Health
CiteScore
1.00
自引率
0.00%
发文量
49
审稿时长
12 weeks
期刊最新文献
High Prescribing: A Case Study of High-Potency Medicinal Cannabis Inducing Psychosis. Doxazosin Immediate Release as a Novel Treatment for Nightmares in Posttraumatic Stress Disorder. Tolerance of Bupropion SR After Delayed-Onset Urticaria and Angioedema Associated With Bupropion XL. Delusional Parasitosis in Comorbidity With Shared Paranoid Disorder in a Marriage. A Boy With KIF11-Associated Disorder Along With ADHD and ASD: Collaboration Between Paediatrics and Child Psychiatry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1